Menu

Latest Pharma Insights



Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease
Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO...
Medtech Insight - March 23, 2023

Finance Watch: Biotech Valuations Seesaw On Bank Failure, Pharma M&A
Public Company Edition: The closure of Silicon Valley Bank sank biotech stocks in the first full week of March, but...
Scrip - March 22, 2023
89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class
89bio’s pegozafermin met co-primary endpoints of fibrosis reduction and NASH resolution in Phase IIb; the company said its methodology yielded...
Scrip - March 22, 2023
Biohaven Makes Bet On Brain-Penetrant TYK2/JAK1 Inhibitor For Neurological Diseases
The company, which has struggled in the clinic following a deal where Pfizer bought its migraine portfolio, is licensing the...
Scrip - March 22, 2023
The ChatGPT Revolution Comes To Pharma Business, Starting With Medical Congresses
ChatGPT’s ability to perform sophisticated analysis and writing tasks has taken the world by storm, and now one developer has...
Scrip - March 22, 2023
Altimmune’s Pemvidutide Garners Mixed Reviews Following Phase II Obesity Data
The US firm’s GLP-1/glucagon receptor agonist improved weight loss in a Phase II interim analysis, but concerns about drug safety...
Scrip - March 22, 2023
Scrip Asks…What Does 2023 Hold For Biopharma? Part 9: The Natural Environment
Improving human health is the raison d’etre of the biopharma sector. But what can the industry do to safeguard and...
Scrip - March 22, 2023
As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics
As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form...
Scrip - March 22, 2023
Allorion Rides Unconventional Discovery Platforms To Major Funding
Allorion's key innovative attractions include discovery platforms for allosteric inhibitor screening and the discovery of synthetic lethality targets/molecules, along with...
Scrip - March 22, 2023

Moderna CEO Hearing Highlights Dissatisfaction With Patient Assistance Programs
There was bipartisan agreement that Moderna need to ensure that its patient assistance program will be easily accessible for under-...
Pink Sheet - March 22, 2023
‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars
With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton –...
Pink Sheet - March 22, 2023
After Xtandi, Will Government Ever Seek March-In Rights Over Drug Pricing?
Market availability of Xtandi, not its cost, is the issue, NIH says in denying petition for government to invoke march-in...
Pink Sheet - March 22, 2023
Accelerated Approval Is US FDA Panel’s Preferred Path For Biogen/Ionis’s Tofersen In ALS
Advisory committee unanimously concludes that the reduction in plasma neurofilament light chain concentration is reasonably likely to predict clinical benefit...
Pink Sheet - March 22, 2023
UK’s Revamped Clinical Trials Framework To Offer Faster Application Review Timelines Than EU
The UK has finalized plans for delivering what it believes will be a stable and streamlined clinical trials framework following...
Pink Sheet - March 22, 2023
Australia To Seek Stakeholder Input On Terms Of HTA Review
The review of the health technology assessment system will look at the use of adaptable and flexible approaches to managing...
Pink Sheet - March 22, 2023

Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease
Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO...
Medtech Insight - March 23, 2023

Cosmetic And Personal Care Weekly Trademarks Review: 21 March
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class...
HBW Insight - March 22, 2023
Errors Coughed Up For Dextromethorphan, Guaifenesin In US FDA Electronic Registrations
Three of seven businesses warned since February 2022 about noncompliance with FDA drug reporting requirements have been marketers of OTC...
HBW Insight - March 22, 2023
Ulta: Beauty Market’s ‘Unprecedented’ Growth Reflects New Trends, Not Just Pandemic Rebound
Growth over the last two years reflects new market dynamics and a growing connection between beauty and wellness, in addition...
HBW Insight - March 22, 2023
Haleon’s Tess Player: Digital Self-Care Can Reduce Health Inequality And Raise Productivity
Haleon's partnership with Microsoft to include 1,500 of the former's products in the latter's Seeing AI application – which reads aloud...
HBW Insight - March 22, 2023
EU Authorizes Cholesterol Lowering Health Claim For Supplement After 10 Year Wait
France's Laboratoire Lescuyer can now claim its Limicol botanical extract supplement "reduces blood LDL-cholesterol concentrations" after waiting more than 10...
HBW Insight - March 22, 2023

Shared Savings Legislation Could Increase Medicare Biosimilar Access
Congressman Richard Hudson has introduced US legislation calling for a three-year ‘demonstration project’ into a shared savings payment scheme for...
Generics Bulletin - March 22, 2023
Sandoz Gains An Edge With High-Concentration US Humira Biosimilar
Sandoz has gained a potential advantage ahead of being part of a second wave of Humira biosimilar competition hitting the...
Generics Bulletin - March 22, 2023
FTC Fights Sage’s Corner In US Apokyn Antitrust Suit
The US Federal Trade Commission has tackled arguments from Supernus Pharmaceuticals, as the firm looks to dismiss an antitrust case...
Generics Bulletin - March 22, 2023

The E in ESG: Philips Drives For Science-Based Targets In Carbon Zero Challenge
With a product mix that includes high energy consumption imaging, capital equipment and personal health care, Philips has a unique...
In Vivo - March 22, 2023
Eyeing Early Chronic Disease Detection Through AI-Based Retinal Scans
South Korean start-up Mediwhale is using AI-guided retinal scans to predict the risk of eye, cardiovascular and kidney diseases. The...
In Vivo - March 22, 2023
How To Develop A Patient-First Strategy For CGT Commercialization
Many new drug commercialization decisions need to happen early in the clinical development of a therapy, and cell and gene...
In Vivo - March 22, 2023
Back to the top Back to the top